Han Jianying, Liu Xueting, Zhang Lixin, Quinn Ronald J, Feng Yunjiang
Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD 4111, Australia.
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
Nat Prod Rep. 2022 Jan 26;39(1):77-89. doi: 10.1039/d1np00011j.
Covering: up to June, 2020Tuberculosis (TB) continues to be a major disease with high mortality and morbidity globally. Drug resistance and long duration of treatment make antituberculosis drug discovery more challenging. In this review, we summarize recent advances on anti-TB natural products (NPs) and their potential molecular targets in cell wall synthesis, protein production, energy generation, nucleic acid synthesis and other emerging areas. We highlight compounds with activity against drug-resistant TB, and reveal several novel targets including biotin synthase, ATP synthase, 1,4-dihydroxy-2-naphthoate prenyltransferase and biofilms. These anti-TB NPs and their targets could facilitate target-based screening and accelerate TB drug discovery.
截至2020年6月
结核病在全球范围内仍然是一种死亡率和发病率都很高的主要疾病。耐药性和治疗周期长使得抗结核药物的研发更具挑战性。在本综述中，我们总结了抗结核天然产物及其在细胞壁合成、蛋白质产生、能量生成、核酸合成和其他新领域潜在分子靶点的最新进展。我们重点介绍了对耐药结核病具有活性的化合物，并揭示了几个新靶点，包括生物素合酶、ATP合酶、1,4-二羟基-2-萘甲酸异戊烯基转移酶和生物被膜。这些抗结核天然产物及其靶点有助于基于靶点的筛选并加速抗结核药物的研发。
